MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00543010
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2002-11
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-11
• Study First Posted: 2007-10-12
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-11
• Last Update Posted: 2015-06-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 247

Inclusion Criteria

• You are taking at least one medication for high blood sugar
• Age 21 to 80

Read More

Exclusion Criteria

• History of Type 1 Diabetes Mellitus
• Currently on estrogen replacement therapy regimen
• Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
• Having surgery 30 days before starting the study
• Have taken any other investigational drug in the past 90 days
• Have Hepatitis B or C
• Active liver or gallbladder disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL